PSS 8 IHC in NSCLC webcast 3

11

description

- PowerPoint PPT Presentation

Transcript of PSS 8 IHC in NSCLC webcast 3

Page 1: PSS 8 IHC in NSCLC webcast 3
Page 2: PSS 8 IHC in NSCLC webcast 3
Page 3: PSS 8 IHC in NSCLC webcast 3
Page 4: PSS 8 IHC in NSCLC webcast 3
Page 5: PSS 8 IHC in NSCLC webcast 3
Page 6: PSS 8 IHC in NSCLC webcast 3
Page 7: PSS 8 IHC in NSCLC webcast 3
Page 8: PSS 8 IHC in NSCLC webcast 3
Page 9: PSS 8 IHC in NSCLC webcast 3
Page 10: PSS 8 IHC in NSCLC webcast 3
Page 11: PSS 8 IHC in NSCLC webcast 3

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLCreagent-catalog.roche.com/documents/PD-L1_SP142-NSCLC-Brochure.pdf · Immun ohistochemical (IHC) staining with the VENTANA

VENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLCreagent-catalog.roche.com/documents/PD-L1_SP142-NSCLC-Brochure.pdf · Immun ohistochemical (IHC) staining with the VENTANA

IHC PPT Ancillary Productsmy1hr-public.s3.amazonaws.com/documents/enroll/IHC PPT Ancillary Products[3].pdfAncillary Products From The IHC Group. The IHC Group Corporate Overview Ø

IHC PPT Ancillary Productsmy1hr-public.s3.amazonaws.com/documents/enroll/IHC PPT Ancillary Products[3].pdfAncillary Products From The IHC Group. The IHC Group Corporate Overview Ø

Nsclc 2nd line

Nsclc 2nd line

Companion & Complementary Diagnostics: Clinical and ... · Immune Checkpoint Inhibitors 1 st Line Treatment in NSCLC • Pembrolizumab/PD-L1 IHC 22C3 pharmDx (KEYNOTE -024) – PD-L1

Companion & Complementary Diagnostics: Clinical and ... · Immune Checkpoint Inhibitors 1 st Line Treatment in NSCLC • Pembrolizumab/PD-L1 IHC 22C3 pharmDx (KEYNOTE -024) – PD-L1

IHC Certification

IHC Certification

Immunohistochemistry (IHC) an Application Guide - …docs.abcam.com/pdf/general/Immunohistochemistry-IHC-Application.pdf · Immunohistochemistry (IHC) an Application Guide 013_13_GM

Immunohistochemistry (IHC) an Application Guide - …docs.abcam.com/pdf/general/Immunohistochemistry-IHC-Application.pdf · Immunohistochemistry (IHC) an Application Guide 013_13_GM

nonsquamous NSCLC

nonsquamous NSCLC

Mlm nsclc prevencion_oportuno_2016_b

Mlm nsclc prevencion_oportuno_2016_b

Precision Medicine & Immunotherapy 2 … · Treatment with pembrolizumab in NSCLC requires PD-L1 IHC testing. Nivolumab and atezolizumab are approved without PD-L1 testing, though

Precision Medicine & Immunotherapy 2 … · Treatment with pembrolizumab in NSCLC requires PD-L1 IHC testing. Nivolumab and atezolizumab are approved without PD-L1 testing, though

PD-L1 IHC 22C3 pharmDx Interpretation Manual, …...Scoring Guidelines 24 Suggested Methods for Determining TPS 25 Identifying Patients with NSCLC for Treatment 27 Reporting Results

PD-L1 IHC 22C3 pharmDx Interpretation Manual, …...Scoring Guidelines 24 Suggested Methods for Determining TPS 25 Identifying Patients with NSCLC for Treatment 27 Reporting Results

PD-L1 IHC 28-8 pharmDx NSCLC Brochure

PD-L1 IHC 28-8 pharmDx NSCLC Brochure

APOBRDU IHC AbD version APOBRDU IHC book.complete.7.19.08

APOBRDU IHC AbD version APOBRDU IHC book.complete.7.19.08

PSS-5, PSS-5/3 - M&C TechGroup · 2020. 7. 14. · PSS® PSS-5, PSS-5/3. Instruction Manual . Version 1.00.04. 2 PSS-5 | 1.00.04 . Dear customer, Thank you for buying our product.

PSS-5, PSS-5/3 - M&C TechGroup · 2020. 7. 14. · PSS® PSS-5, PSS-5/3. Instruction Manual . Version 1.00.04. 2 PSS-5 | 1.00.04 . Dear customer, Thank you for buying our product.

Nsclc slide deck

Nsclc slide deck

Cancer genomics and personalised medicine: a pathologist’s ......HER2+ breast cancer 1998 ... Molecular testing No molecular testing..yet NSCLC subtype IHC EGFR ALK ROS RET NTRK1.

Cancer genomics and personalised medicine: a pathologist’s ......HER2+ breast cancer 1998 ... Molecular testing No molecular testing..yet NSCLC subtype IHC EGFR ALK ROS RET NTRK1.

6_DB & IHC

6_DB & IHC

IHC ROBBINS aBOUt CapaBIlIty IHC ROBBINS IHCROBBINS.COM ...

IHC ROBBINS aBOUt CapaBIlIty IHC ROBBINS IHCROBBINS.COM ...

NSCLC - Stage IV STAGE IVNSCLC. NSCLC - Stage IV NSCLC Main Drugs Stage IV NAVELBINE:The pivotal drug GEMZAR:Main competitor TAXOL:Still often prescribed.

NSCLC - Stage IV STAGE IVNSCLC. NSCLC - Stage IV NSCLC Main Drugs Stage IV NAVELBINE:The pivotal drug GEMZAR:Main competitor TAXOL:Still often prescribed.

PD-L1 Testing German Experiencemedia.aiom.it/userfiles/files/doc/AIOM-Servizi/... · PD-L1 NSCLC; final report EGFR IHC sqNSCLC. final report PD-L1 Melanoma (2) final report T790M

PD-L1 Testing German Experiencemedia.aiom.it/userfiles/files/doc/AIOM-Servizi/... · PD-L1 NSCLC; final report EGFR IHC sqNSCLC. final report PD-L1 Melanoma (2) final report T790M

Re-imaging the airport network for 2020 and beyondglobaltransportupdate.com/wp-content/uploads/2015/11/Reimagining... · PSS-64 PSS-36 PSS-32 PSS-16 PSS-8 PSS-4 MPT MSS-0/1/4/8 ...

Re-imaging the airport network for 2020 and beyondglobaltransportupdate.com/wp-content/uploads/2015/11/Reimagining... · PSS-64 PSS-36 PSS-32 PSS-16 PSS-8 PSS-4 MPT MSS-0/1/4/8 ...